Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Patients With B-Cell Hematologic Malignancies on Ibrutinib Therapy Who Are Infected With Coronavirus Disease 2019 (COVID-19)

NCT04665115 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT04665115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Patients With B-Cell Hematologic Malignancies on Ibrutinib Therapy Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Withdrawn
Start date
November 23, 2020
Completion date
July 22, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asymptomatic covid-19 infection laboratory-confirmed, b-cell neoplasm, chronic lymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, symptomatic covid-19 infection laboratory-confirmed, waldenstrom macroglobulinemia